National survey of drug-resistant tuberculosis in China

New England Journal of Medicine

Volumn 366, Issue 23, 2012, Pages 2161-2170

  Zhao, Yanlin ^a,b   Xu, Shaofa ^b   Wang, Lixia ^a   Chin, Daniel P ^c   Wang, Shengfen ^a   Jiang, Guanglu ^b   Xia, Hui ^a   Zhou, Yang ^a   Li, Qiang ^a   Ou, Xichao ^a   Pang, Yu ^a   Song, Yuanyuan ^a   Zhao, Bing ^a   Zhang, Hongtao ^b   He, Guangxue ^a   Guo, Jing ^d   Wang, Yu ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d PEOPLE'S UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HOSPITAL PLANNING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

EID: 84861874346     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1108789     Document Type: Article

References (32)

1. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis - critical steps for prevention and control. N Engl J Med 2010;363:1050-8.
2. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: World Health Assembly resolution 62.15, May 2009 (http://apps.who.int/gb/ebwha/pdf-files/ A62/A62-R15-en.pdf).
3. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375: 1830-43.
4. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization, 2010 (WHO/ HTM/TB/2010.3).
5. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
6. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. N Engl J Med 2001; 344:1294-303. (Pubitemid 32377203)
7. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001;5:887-93. (Pubitemid 32976631)
8. Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 2009;13:68-73.
9. Aguiar F, Vieira MA, Staviack A, et al. Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2009;13:54-61.
10. Clark CM, Li J, Driver CR, Munsiff SS. Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City. Int J Tuberc Lung Dis 2005;9: 964-9. (Pubitemid 41549182)
11. Boonsarngsuk V, Tansirichaiya K, Kiatboonsri S. Thai drug-resistant tuberculosis predictive scores. Singapore Med J 2009;50:378-84.
12. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009;150:766-75.
13. Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis 2009; 13:253-9.
14. Telles MAS, Ferrazoli L, Waldman EA, et al. A population-based study of drug resistance and transmission of tuberculosis in an urban community. Int J Tuberc Lung Dis 2005;9:970-6. (Pubitemid 41549183)
15. Moniruzzaman A, Elwood RK, Schulzer M, FitzGerald JM. A population-based study of risk factors for drug-resistant TB in British Columbia. Int J Tuberc Lung Dis 2006;10:631-8. (Pubitemid 43845024)
16. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14:382-90.
17. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: World Health Organization, 2009 (WHO/HTM/ TB/2009.422).
18. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization, 2003 (WHO/CDS/ TB/2003.313).
19. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963;29:565-78.
20. World Health Organization. Tuberculosis (TB) (http://www.who.int/tb/ country/ data/download/en/index.html).
21. Engaging all health care providers in TB control: guidance on implementing public-private mix approaches. Geneva: World Health Organization, 2006 (WHO/ HTM/TB/2006.360).
22. Wang L, Liu J, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet 2007;369:691-6.
23. Barclay E. Text messages could hasten tuberculosis drug compliance. Lancet 2009;373:15-6. [Erratum, Lancet 2009;373: 632.]
24. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010;376:1838-45.
25. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100-9.
26. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008;178:306-12.
27. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008;149:123-34. (Pubitemid 352008599)
28. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6(9):e1000150.
29. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004;8:31-8. (Pubitemid 38120703)
30. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15.
31. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organization, 2011 (WHO/HTM/ TB/2011.4).
32. Small PM, Pai M. Tuberculosis diagnosis - time for a game change. N Engl J Med 2010;363:1070-1.